๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2

โœ Scribed by Diaz, Miguel; Abdul, Mansoor; Hoosein, Naseema


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
197 KB
Volume
36
Category
Article
ISSN
0270-4137

No coin nor oath required. For personal study only.

โœฆ Synopsis


Neuroendocrine differentiation in prostate cancer has received much attention recently because it has been found to be associated with androgen independence and shortened patient survival in some studies. We have investigated the effect of the cytokines interleukin-1 (IL-1), IL-2, and IL-6 on the expression of the neuroendocrine marker chromogranin A in human prostate cancer cell lines. Chromogranin A was measured by fluorescenceimmunoassay, as well as by immunoblotting. We find that IL-1โค and IL-6 increase the cellular content and chromogranin A secretion by LNCaP and DU-145 cells. By contrast, IL-2 decreases the cellular and secreted chromogranin A levels in the two cell lines. Our results suggest that these proinflammatory cytokines can influence neuroendocrine differentiation in prostate cancer and be involved in disease progression.


๐Ÿ“œ SIMILAR VOLUMES


Differentiation-promoting effect of 1-O
โœ Hongmei Wang; Sriram Rajagopal; Sharon Reynolds; Hokan Cederberg; Subhas Chakrab ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 127 KB ๐Ÿ‘ 2 views

Alkylglycerols are naturally occurring bioactive ether lipids found in great abundance in the livers of many marine species. In this study, we evaluated the differentiation-promoting potential of a methoxy substituted alkylglycerol-1-O (2 methoxy) hexadecyl glycerol (MHG)-to promote a more benign or

Deletional, mutational, and methylation
โœ David F. Jarrard; G. Steven Bova; Charles M. Ewing; Sokhom S. Pin; Son H. Nguyen ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 98 KB

The tumor suppressor gene CDKN2 (p16/MTS1) resides on chromosome 9p21 and encodes a 16 kDa inhibitor of the cyclin-dependent kinases. Inactivation of CDKN2 by homozygous deletion, point mutation, and recently described aberrant methylation in the 5' promoter region may increase progression through t